Literature DB >> 32151629

Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults.

Lucia Seminario-Vidal1, Daniela Kroshinsky2, Stephen J Malachowski3, James Sun4, Alina Markova5, Thomas M Beachkofsky6, Benjamin H Kaffenberger7, Elizabeth N Ergen8, Melissa Mauskar9, Alina Bridges10, Cody Calhoun7, Adela R Cardones11, Steven T Chen2, James Chodosh12, Jonathan Cotliar13, Mark D P Davis10, Katherine L DeNiro14, Arturo R Dominguez15, Juliana Eljure-Téllez16, Alisa Femia17, Lindy P Fox18, Anisha Guda19, Caroline Mitchell20, Arash Mostaghimi21, Alex G Ortega-Loayza22, Cindy Owen23, Helena Pasieka24, Sahand Rahnama-Moghadam25, Hajirah N Saeed12, Rebecca B Saunderson26, Swapna Shanbhag27, Victoria R Sharon28, Lindsay Strowd29, Samantha Venkatesh30, Karolyn A Wanat31, David A Wetter10, Scott Worswick32, Robert G Micheletti33.   

Abstract

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening conditions with high morbidity and mortality. Supportive care management of SJS/TEN is highly variable. A systematic review of the literature was performed by dermatologists, ophthalmologists, intensivists, and gynecologists with expertise in SJS/TEN to generate statements for supportive care guideline development. Members of the Society of Dermatology Hospitalists with expertise in SJS/TEN were invited to participate in a modified, online Delphi-consensus. Participants were administered 9-point Likert scale questionnaires regarding 135 statements. The RAND/UCLA Appropriateness Method was used to evaluate and select proposed statements for guideline inclusion; statements with median ratings of 6.5 to 9 and a disagreement index of ≤1 were included in the guideline. For the final round, the guidelines were appraised by all of the participants. Included are an evidence-based discussion and recommendations for hospital setting and care team, wound care, ocular care, oral care, urogenital care, pain management, infection surveillance, fluid and electrolyte management, nutrition and stress ulcer prophylaxis, airway management, and anticoagulation in adult patients with SJS/TEN.
Copyright © 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Society of Dermatology Hospitalists; Stevens-Johnson syndrome; dermatology consultation; inpatient; severe cutaneous adverse reaction; toxic epidermal necrolysis

Year:  2020        PMID: 32151629     DOI: 10.1016/j.jaad.2020.02.066

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  5 in total

1.  Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis-Coordinating Research Priorities to Move the Field Forward.

Authors:  Elizabeth J Phillips; Charles S Bouchard; Sherrie J Divito
Journal:  JAMA Dermatol       Date:  2022-06-01       Impact factor: 11.816

Review 2.  Genetic Markers for Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in the Asian Indian Population: Implications on Prevention.

Authors:  Swapna S Shanbhag; Madhuri A Koduri; Chitra Kannabiran; Pragnya R Donthineni; Vivek Singh; Sayan Basu
Journal:  Front Genet       Date:  2021-01-12       Impact factor: 4.599

Review 3.  NLRP3 Inflammasome: A Promising Therapeutic Target for Drug-Induced Toxicity.

Authors:  Shanshan Wei; Wanjun Ma; Bikui Zhang; Wenqun Li
Journal:  Front Cell Dev Biol       Date:  2021-04-12

Review 4.  Vulvovaginal and ocular involvement and treatment in female patients with Stevens-Johnson syndrome and toxic epidermal necrolysis: A review.

Authors:  M Teresa Magone; Mary Maiberger; Janine Clayton; Helena Pasieka
Journal:  Int J Womens Dermatol       Date:  2021-09-02

5.  Moderate Psoriasis in Clinical Practice: French Expert Consensus Using a Modified Delphi Method.

Authors:  Marie-Aleth Richard; François Aubin; Nathalie Beneton; Anne Bouloc; Anne-Claire Bursztejn; Vincent Descamps; Denis Jullien
Journal:  Adv Ther       Date:  2022-09-16       Impact factor: 4.070

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.